TNGX · CIK 0001819133 · operating
Tango Therapeutics is a precision oncology company focused on discovering and developing targeted cancer drugs for patient populations defined by specific genetic alterations. The company's pipeline centers on two primary mechanisms: PRMT5 inhibition and transcriptional reprogramming. TNG462, a PRMT5 inhibitor, is in Phase 1/2 clinical development for pancreatic and lung cancers, while TNG456, a brain-penetrant variant of the same class, targets glioblastoma. The company is also developing TNG260, a transcriptional co-repressor inhibitor designed to restore immune function in lung cancer patients with STK11 loss-of-function mutations.
The company operates primarily in the biotechnology and pharmaceutical development space, with revenue generation expected to emerge from clinical milestone achievements and potential future commercialization of approved therapies. Currently, Tango Therapeutics maintains operations in Boston, Massachusetts, where it was founded in 2017, with a workforce of approximately 155 full-time employees. As a public company listed on Nasdaq, Tango funds its research and development activities through capital markets and milestone-based partnerships.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.19 | $-1.19 | -10.2% | |
| 2023 | $-1.08 | $-1.08 | +12.2% | |
| 2022 | $-1.23 | $-1.23 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |